BR0012200B1 - composição de peptídeo para o tratamento de disfunção sexual e composição farmacêutica para o tratamento de disfunção sexual em um mamífero. - Google Patents

composição de peptídeo para o tratamento de disfunção sexual e composição farmacêutica para o tratamento de disfunção sexual em um mamífero.

Info

Publication number
BR0012200B1
BR0012200B1 BRPI0012200-9B1A BR0012200A BR0012200B1 BR 0012200 B1 BR0012200 B1 BR 0012200B1 BR 0012200 A BR0012200 A BR 0012200A BR 0012200 B1 BR0012200 B1 BR 0012200B1
Authority
BR
Brazil
Prior art keywords
sexual dysfunction
treating sexual
mammal
composition
pharmaceutical composition
Prior art date
Application number
BRPI0012200-9B1A
Other languages
English (en)
Other versions
BR0012200A (pt
Inventor
Christine H Blood
Annette M Shadiack
Joanna K Bernstein
Guy W Herbert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR0012200A publication Critical patent/BR0012200A/pt
Publication of BR0012200B1 publication Critical patent/BR0012200B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
BRPI0012200-9B1A 1999-06-29 2000-06-29 composição de peptídeo para o tratamento de disfunção sexual e composição farmacêutica para o tratamento de disfunção sexual em um mamífero. BR0012200B1 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14234699P 1999-06-29 1999-06-29
US19498700P 2000-04-05 2000-04-05
US09/606,501 US6579968B1 (en) 1999-06-29 2000-06-28 Compositions and methods for treatment of sexual dysfunction
PCT/US2000/018217 WO2001000224A1 (en) 1999-06-29 2000-06-29 Compositions and methods for treatment of sexual dysfunction

Publications (2)

Publication Number Publication Date
BR0012200A BR0012200A (pt) 2002-03-26
BR0012200B1 true BR0012200B1 (pt) 2013-08-06

Family

ID=27385799

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0012200-9B1A BR0012200B1 (pt) 1999-06-29 2000-06-29 composição de peptídeo para o tratamento de disfunção sexual e composição farmacêutica para o tratamento de disfunção sexual em um mamífero.

Country Status (15)

Country Link
US (3) US6579968B1 (pt)
EP (1) EP1196184B8 (pt)
JP (1) JP4576493B2 (pt)
KR (1) KR101021632B1 (pt)
AT (1) ATE293453T1 (pt)
AU (1) AU783718B2 (pt)
BR (1) BR0012200B1 (pt)
CA (1) CA2376978C (pt)
DE (1) DE60019598T2 (pt)
ES (1) ES2235921T3 (pt)
HK (1) HK1047881B (pt)
MX (1) MXPA02000111A (pt)
NZ (1) NZ516030A (pt)
PT (1) PT1196184E (pt)
WO (1) WO2001000224A1 (pt)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7258850B2 (en) * 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
AU766191B2 (en) 1999-06-04 2003-10-09 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US7176279B2 (en) * 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
CZ2003788A3 (cs) * 2000-09-27 2003-08-13 The Procter & Gamble Company Ligandy melanokortinového receptoru
AU2002238106A1 (en) 2001-02-13 2002-08-28 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
US7342089B2 (en) * 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
AU2002331064B2 (en) * 2001-08-10 2007-08-23 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US6873883B2 (en) * 2001-12-26 2005-03-29 Hewlett-Packard Development Company, L.P. Adaptive fan controller for a computer system
JP2005524649A (ja) * 2002-02-25 2005-08-18 カイロン コーポレーション Ｍｃ４−ｒアゴニストの鼻腔内投与
US8043287B2 (en) * 2002-03-05 2011-10-25 Kimberly-Clark Inc. Method of treating biological tissue
DE10228837B4 (de) * 2002-06-27 2016-01-07 Elfriede Rauch Hautkosmetische Zusammensetzung und Verwendung der Zusammensetzung als Hautbräunungsmittel
AU2003248888A1 (en) * 2002-07-09 2004-01-23 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
CN1744917B (zh) * 2003-02-26 2010-05-05 大塚制药株式会社 经肺给药用缓释性制剂学组合物
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US20050101535A1 (en) * 2003-05-06 2005-05-12 Rosenstein David H. Use of a synthetic alpha-melanocyte stimulating hormone agonist to decrease steroid induced weight gain
US20060293223A1 (en) * 2003-06-19 2006-12-28 Eli Lilly And Company Patent Division Uses of melanocortin-3 receptor (mc3r) agonist peptides
KR20060014444A (ko) * 2003-06-19 2006-02-15 일라이 릴리 앤드 캄파니 멜라노코르틴 수용체 4 (ｍｃ4) 작용제 및 그의 용도
CN101497654A (zh) 2003-09-30 2009-08-05 诺沃挪第克公司 黑皮素受体激动剂
US7550602B1 (en) * 2004-01-14 2009-06-23 Palatin Technologies, Inc. Small molecule compositions for sexual dysfunction
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
NZ551340A (en) * 2004-04-22 2010-10-29 Boehringer Ingelheim Int Pharmaceutical composition comprising flibanserin and a melanocortin agonist for the treatment of premenstrual disorder or sexual aversion disorder
TW200626611A (en) * 2004-09-20 2006-08-01 Lonza Ag Peptide cyclisation
WO2006060873A1 (en) * 2004-12-09 2006-06-15 Prince Henry's Institute Of Medical Research Method for restoring reproductive function
PT2286825T (pt) * 2005-07-08 2017-01-02 Ipsen Pharma Sas Ligandos do recetor de melanocortina
CA2617546C (en) 2005-08-03 2014-07-15 Boehringer Ingelheim International Gmbh Use of flibanserin in the treatment of obesity
CA2617654A1 (en) * 2005-08-04 2007-02-08 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
US20080227693A1 (en) * 2005-08-29 2008-09-18 Palatin Technologies, Inc. Cyclic Peptide Isolation by Spray Drying
US7923449B2 (en) 2005-10-29 2011-04-12 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US8247530B2 (en) * 2005-11-08 2012-08-21 Palatin Technologies, Inc. N-alkylated cyclic peptide melanocortin agonists
CN101092451B (zh) * 2006-06-20 2011-02-09 中国人民解放军军事医学科学院毒物药物研究所 Pt-141和mt-ⅱ的固相合成方法
DE602007004615D1 (de) 2006-06-30 2010-03-18 Boehringer Ingelheim Pharma Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
AU2007286288A1 (en) 2006-08-14 2008-02-21 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
BRPI0716436B8 (pt) 2006-08-25 2021-05-25 Boehringer Ingelheim Int sistema de liberação controlada e método para fabricação do mesmo
CN101195654B (zh) * 2006-12-08 2011-06-15 上海吉尔多肽有限公司 一种美拉诺坦-ⅱ的固相合成方法
CA2672957C (en) 2006-12-20 2015-04-14 Boehringer Ingelheim International Gmbh Sulfated benzimidazolone derivatives having mixed serotonine receptor affinity
WO2008091355A2 (en) * 2007-01-24 2008-07-31 Breathe Pharmaceuticals, Inc. Drug transfer device
CN101280005B (zh) * 2007-04-06 2013-03-13 扬子江药业集团四川海蓉药业有限公司 普美拉肽的制备方法
UY31335A1 (es) 2007-09-12 2009-04-30 Tratamiento de sintomas vasomotores
WO2009120656A1 (en) * 2008-03-24 2009-10-01 Palatin Technologies, Inc. Pharmaceutical for ocular indications
WO2009144433A1 (en) * 2008-05-30 2009-12-03 Palatin Technologies, Inc. Methods for selection of melanocortin 4 receptor-specific agents for treatment of obesity
AR072072A1 (es) * 2008-06-09 2010-08-04 Palatin Technologies Inc Peptidos especificos del receptor de melanocortina para el tratamiento de la obesidad / 669
CN102131514B (zh) 2008-06-09 2014-08-20 帕拉丁科技公司 用于治疗性功能障碍的黑皮质素受体特异性肽
MX2011003117A (es) * 2008-09-19 2011-04-21 Nektar Therapeutics Conjugados polimericos de peptidos terapeuticos.
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
MX2011013117A (es) * 2009-06-08 2012-05-23 Palatin Technologies Inc Peptidos especificos del receptor de melanocortina.
WO2011063366A1 (en) 2009-11-23 2011-05-26 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
EA201290295A1 (ru) 2009-11-23 2013-01-30 Палатин Текнолоджиз, Инк. Специфичные к рецептору меланокортина-1 линейные пептиды
CA2797033C (en) 2010-04-22 2021-10-19 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
US9415012B2 (en) 2011-06-14 2016-08-16 Ipsen Pharma S.A.S. Sustained-release composition containing peptides as active ingredient
WO2013067309A1 (en) 2011-11-04 2013-05-10 Xion Pharmaceutical Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
BR112015009936A8 (pt) 2012-11-05 2019-09-17 Palatin Technologies Inc uso de uma dose de formulação; bremelanotide para uso em um método para tratar disfunção sexual feminina; e unidade de dose pré-carregada
CA2892134C (en) 2012-11-21 2022-10-04 University Of Cincinnati Skin care compositions and methods comprising selective agonists of melanocortin 1 receptor
US9789164B2 (en) 2013-03-15 2017-10-17 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
US9821023B2 (en) 2014-06-10 2017-11-21 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for the treatment of central nervous system (CNS) disorders and mood disorders
US20170022252A1 (en) 2014-06-10 2017-01-26 The Arizona Board Of Regents On Behalf Of The University Of Arizona Novel modulators of melanocortin receptors
US9814755B2 (en) 2014-06-10 2017-11-14 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for the treatment of depression and anxiety
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
WO2017066769A1 (en) * 2015-10-16 2017-04-20 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating central nervous system (cns) disorders and mood disorders
US10550157B2 (en) 2015-10-16 2020-02-04 Arizona Board Of Regent On Behalf Of The University Of Arizona Compositions and methods for treating central nervous system (CNS) disorders and mood disorders
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN106243214B (zh) * 2016-08-29 2019-12-10 济南康和医药科技有限公司 一种美拉诺坦ⅰ的制备方法
RU2655763C2 (ru) * 2016-10-24 2018-05-29 Общество С Ограниченной Ответственностью "Айвикс" Фармацевтическая композиция и способ лечения женских сексуальных дисфункций
WO2021158464A1 (en) * 2020-02-03 2021-08-12 Palatin Technologies, Inc. Reverse amide-linked melanocortin receptor-specific cyclic peptides
EP4100040A4 (en) * 2020-02-03 2024-06-05 Palatin Technologies, Inc. DIAMINE-LINKED RECEPTOR-SPECIFIC CYCLIC PEPTIDES

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862928A (en) * 1969-07-09 1975-01-28 Akzona Inc Psychopharmacological hexa-peptides containing a d-phenylalanyl residue
BE795788A (nl) * 1972-02-22 1973-08-22 Akzo Nv Werkwijze ter bereiding van peptiden en peptide-derivaten en de toepassing hiervan
US4649191A (en) * 1984-05-10 1987-03-10 Gibson-Stephens Neuropharmaceuticals, Inc. Conformationally constrained alpha-melanotropin analogs with specific central nervous system activity
US4623715A (en) * 1984-10-22 1986-11-18 Hoechst Aktiengeselleschaft Novel peptides which are active on the central nervous system and have an action on the cholinergic system
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
AU7880991A (en) 1990-05-10 1991-11-27 Novo Nordisk A/S A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols
FR2691465B1 (fr) * 1992-05-25 1995-08-11 Pf Medicament Complexes comprenant au moins un peptide derive de l'alpha msh, peptide, microsphere, medicament et composition galenique les comprenant.
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
EP0696919B1 (en) 1993-04-05 2002-01-30 Competitive Technologies, Inc. Diagnosis and treatment of erectile dysfunction
US5420109A (en) * 1993-11-12 1995-05-30 Houghten Pharmaceuticals, Inc. Cytokine restraining agents
US6054556A (en) 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
FR2735131B1 (fr) * 1995-06-12 1997-08-22 Rech De Pathologie Appliquee S Conjugues d'msh avec un acide gras, leur procede de preparation et leur utilisation a titre de medicament
US5908825A (en) 1997-01-09 1999-06-01 University Of Maryland At Baltimore Dosage composition for nasal delivery and method of use of the same
WO1999021571A1 (en) 1997-10-27 1999-05-06 Trega Biosciences, Inc. Melanocortin receptor ligands and methods of using same
US6228840B1 (en) 1998-02-27 2001-05-08 Edward T. Wei Melanocortin receptor antagonists and modulations of melanocortin receptor activity
EP1076649A4 (en) 1998-04-28 2010-06-02 Trega Biosciences Inc ISOQUINOLINE-BASED COMPOUNDS IN PLACE OF MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USE
WO1999064002A1 (en) 1998-06-11 1999-12-16 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction

Also Published As

Publication number Publication date
US20050037951A1 (en) 2005-02-17
KR20020016876A (ko) 2002-03-06
US20020107182A1 (en) 2002-08-08
WO2001000224A1 (en) 2001-01-04
ATE293453T1 (de) 2005-05-15
CA2376978C (en) 2012-11-20
JP2003503357A (ja) 2003-01-28
NZ516030A (en) 2004-10-29
AU6340700A (en) 2001-01-31
US6579968B1 (en) 2003-06-17
EP1196184B1 (en) 2005-04-20
KR101021632B1 (ko) 2011-03-17
EP1196184A4 (en) 2003-05-28
HK1047881A1 (en) 2003-03-14
EP1196184A1 (en) 2002-04-17
EP1196184B8 (en) 2005-06-15
US6794489B2 (en) 2004-09-21
BR0012200A (pt) 2002-03-26
ES2235921T3 (es) 2005-07-16
HK1047881B (zh) 2005-10-14
PT1196184E (pt) 2005-08-31
DE60019598D1 (de) 2005-05-25
DE60019598T2 (de) 2005-09-29
CA2376978A1 (en) 2001-01-04
AU783718B2 (en) 2005-12-01
MXPA02000111A (es) 2003-07-21
JP4576493B2 (ja) 2010-11-10

Similar Documents

Publication Publication Date Title
BR0012200B1 (pt) composição de peptídeo para o tratamento de disfunção sexual e composição farmacêutica para o tratamento de disfunção sexual em um mamífero.
TW487711B (en) Conjugates of lipophilic moieties and peptides
CA2338005A1 (en) Peptide antagonists of zonulin and methods for use of the same
CY1107051T1 (el) Αντι-διηθητικα και αντι-αγγειογενετικα θραυσματα ουροκινασης και η χρηση τους
NO993520D0 (no) Doseringsformer og fremgangsmåte for å bedre erektil dysfunksjon
KR960703015A (ko) 후천성 면역결핍증 치료용 약물의 제조시 노나- 및 데카펩타이드의 용도(Use of nona-and decapeptides in the preparation of a durg for the treatment of AIDS)
EP1033998A4 (en) METHOD FOR SUPPRESSING BETA AMYLOID-RELATED CHANGES IN ALZHEIMER
WO2005014617A3 (en) Cyclic peptide compositions and methods for treatment of sexual dysfunction
HK1160778A1 (en) Pharmaceutical composition comprising an analgesic peptide
NZ516477A (en) Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
EP0981360A4 (en) METHOD FOR PREVENTING GASTRITIS USED BY AMYLIN OR AMYLIN AGONISTS
ATE205219T1 (de) Ein verbessertes peptid, immunogene zusammensetzung und impfstoff oder medizinische präparate, eine methode zur immunisierung von tieren gegen das hormon lhrh und analoge des lhrh-tendem-repeat-peptid und deren verwendung als impfstoff
IT1244496B (it) Impiego terapeutico dei peptidi della somatostatina.
DE60031259D1 (de) Nährstoffe aus sojabohnenprotein
KR970701724A (ko) 스타니어스 단백질인 스타니오칼신의 소체(Corpuscles of stannius protein, stanniocalcin)
MXPA02008870A (es) Novedosos antagonistas de lhrh, produccion de los mismos y sus uso como medicamentos.
EP1593384A3 (en) Compositions for treatment of sexual dysfunction
BR0015446A (pt) Peptìdios para o tratamento de disfunção erétil
HK1092162A1 (en) Biologically active peptides comprising isoleucyl-valyl-threonyl- asparaginyl-threonyl-threonine (ivtntt)
JPH0372044B2 (pt)
AU4918900A (en) Interferon-beta use in the treatment of ewing's family of tumors
EP1372691A4 (en) MUCINPEPTIDE WITH IMMUNOSIBLE PROPERTIES
UA36167A (uk) Спосіб лікування панкреатиту
KR920700675A (ko) 발기 기능장해 치료용 약물(칼시토닌 유전자 관련 펩티드)
UA35918A (uk) Спосіб лікування червоного плескатого лишаю слизової оболонки порожнини рота

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2013, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2594 DE 24-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.